$NVLX has developed a technology that reduces diabetic's dependency on insulation administration by being able to add new living pancreas cells to the human body which could greatly improve the lives of more than 370 million people worldwide, and even take a large chunk of the market segment, which is estimated to be $65 billion annual in the U.S. by 2020.